Tempus Next Intelligence

Clinical intelligence solutions for oncology life sciences.

Contact usLog in

AI-powered clinical intelligence

Tempus Next Intelligence for oncology life sciences is an AI-powered platform that leverages unstructured and structured data, allowing life sciences companies access to a near-real time, granular, de-identified view of patient journey data.

 

Access comprehensive and actionable insights from a continually growing dataset, empowering teams to monitor guideline adherence, identify and quantify care gaps, and make data-driven decisions to accelerate oncology programs.

Next Intelligence Actionable Insights

Transform complex, real-world data into actionable insights

 

AI-powered platform designed to surface deep insights from multi-modal and longitudinal patient data, extracting relevant clinical data to contextualize demographic, clinical, health system, and geographic details around care gap occurrence.

Breast cancer dashboard displaying advanced diagnosis types and metastatic patterns with therapy data.

Access a dynamic view of the patient journey

 

Dynamic and granular view of testing, treatment adherence, and care gaps, providing insight into the state of guideline-directed precision medicine and gaining an unbiased understanding of patient journeys.

Sankey diagram showing user progression through a website application process with various stages.

Advance equitable access to care

 

Next Intelligence helps improve timely and accurate diagnostics, procedures and therapies for patients, regardless of socioeconomic status. This analysis helps identify testing disparities and specific barriers to support health equity research.

Map of the United States showing geographic patterns and regional trends with blue-highlighted areas.

Resources

A white circle partially overlapping a solid white square against a dark background.Case Study
BMS-Case-Study_thumbnail

Tempus Next Pathways unlocked critical insights into the aNSCLC patient journey with Bristol Myers Squibb (BMS)

Discover how BMS collaborated with Tempus to deploy the Next Pathways program across 13 community-based health systems to address care gaps for patients with advanced non-small cell lung cancer (aNSCLC).

A white circle partially overlapping a solid white square against a dark background.Case Study
Digital document detailing an algorithmic approach for patient care gaps and HER2 testing.

An algorithmic approach to close care gaps for patients that may benefit from confirmatory IHC HER2 testing

Learn how Tempus, in partnership with a global pharmaceutical company, deployed a HER2 predictive algorithm at selected sites within the Tempus network to identify patients who may benefit from additional confirmatory IHC HER2 testing.

A white circle partially overlapping a solid white square against a dark background.Case Study
Case study document detailing how Tempus Next closes the biomarker testing gap for NSCLC patients.

Closing the biomarker testing gap for early stage NSCLC (Non-small cell lung cancer) patients with Tempus Next

In the 25 weeks from deployment at TriHealth Cancer and Blood Institute in Cincinnati, Ohio, compliance with targeted biomarker testing guidelines for resectable stage IB-III NSCLC increased to 100%.

White square with a folded top-left corner on a dark background.Webinar
Mercy logo with a cross symbol, indicating a healthcare or religious organization.

Navigating New Frontiers in Breast Cancer Care Pathway Intelligence: The Role of Providers and AI

Learn how Mercy Health System is using Tempus Next to support providers in delivering guideline directed and personalized breast cancer care.

This is AI-enabled precision medicine

This is the future of healthcare.